Home
>
US Stocks
>
ImmunityBio Inc
ImmunityBio Inc
IBRX

ImmunityBio Inc (IBRX)

$8.2724.13%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
8.3
Today Low/High
8.12 / 8.32
52 Week Low/High
$6.03 / $45.42
Market Cap
$3.93B

Company Details

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Organisation
ImmunityBio Inc
Headquaters
San Diego, California, US
Employees
171
CEO
Patrick Soon-Shiong

Discover more

Frequently Asked Questions

What is ImmunityBio Inc (IBRX) share price today?

Can Indians buy ImmunityBio Inc (IBRX) shares?

How can I buy ImmunityBio Inc (IBRX) shares from India?

Can Fractional shares of ImmunityBio Inc (IBRX) be purchased?

What are the documents required to start investing in ImmunityBio Inc (IBRX) stocks?

We are a SEBI registered investement advisor